


Expansion of Specimen Types for Influenza Rapid Antigen Test

~For acceleration of simultaneous detection of both influenza and SARS-CoV-2 by expanding and clarifying specimen types for the test~

On October 30th, Denka Company Limited (headquarters: Chuo-ku, Tokyo; president: Manabu Yamamoto; hereinafter, “Denka”) has received approval from the Ministry of Health, Labour and Welfare to partially change the market authorization for QuickNavi™-Flu2, an influenza rapid antigen test*. The approval enables the use of a nasal swab specimen for QuickNavi™-Flu2 and as a result, now both influenza and SARS-CoV-2 can be tested with a single specimen, which is recommended by the Japanese Association for Infectious Diseases. This expansion of specimen type is expected to accelerate the current diagnostic systems in clinics and hospitals.

As with QuickNavi™-COVID19 Ag, a nasal swab specimen collected by a patient has been allowed to be used with QuickNavi™-Flu2 under supervision of a healthcare professional. This will reduce of the risk of transmission to healthcare professionals and the burden on patients. Approval of this partial change also applies to products marketed by our distributor, Otsuka Pharmaceutical Co., Ltd. (headquarters: Chiyoda-ku, Tokyo; president: Makoto Inoue).

●鼻腔ぬぐい液




【鼻腔ぬぐい液の採取方法】

- 鼻腔用滅菌綿棒を外鼻孔から2cm程度挿入します。
- 綿棒を5回転させ、5秒程度静置し、検体を採取します。

【ご注意】 被検者自身が採取する際は、鼻出血が起こりやすい部位である点にも配慮し、医療従事者の管理下で実施する*。

*新型コロナウイルス感染症(COVID-19)病原体検査の指針(第1版)より引用。

●鼻咽頭ぬぐい液



【鼻咽頭ぬぐい液の採取方法】

- 鼻腔用滅菌綿棒を外鼻孔から鼻腔に挿入し、鼻咽頭を数回擦過して検体を採取します。

* Description change:

Previous: nasal swab specimen → New: nasopharyngeal swab specimen and nasal swab specimen

Specimen type	QuickNavi™-Flu2	QuickNavi™-COVID19 Ag
Nasopharyngeal swab specimen	○	○
Nasal swab specimen	○	○

Denka considers the fight against infectious diseases to be its social responsibility and, with the cooperation and support of relevant authorities, public agencies and research institutions in Japan and overseas, is conducting research and development from various perspectives to meet the needs of healthcare professionals and contribute people's quality of life by help improve prevention and diagnostic systems. Denka will promptly make an announcement if this development is expected to have a material impact on Denka's consolidated financial results for FY2020.

* COVID-19 Pathogen Testing Guideline (First Edition) and notes on collecting a sample from nasal cavity, COVID-19 Control Task Force, Ministry of Health, Labour and Welfare (October 2, 2020) *Japanese

<https://www.mhlw.go.jp/content/000678570.pdf>

Reference: Related past release (Denka's website):

• October 2, 2020, Expansion of Intended Use and Specimen Types for Denka's COVID 19 Ag Rapid Test kit
~To diminish healthcare and patient burden in SARS-CoV-2 and Influenza antigen testing~

https://www.denka.co.jp/storage/news/pdf/768/20201002_denka_quicknavi.pdf

About Denka

Denka is a chemical manufacturer headquartered in Chuo-ku, Tokyo. The company specializes in developing business activities on a global scale across a wide range of fields, from inorganic and organic chemicals, to electronic materials and pharmaceuticals. Founded in 1915, Denka has steadily continued to develop and manufacture products that contribute to the development of society by fully utilizing its unique concepts and technological capabilities. Upholding its corporate slogan, "Possibility of chemistry," the company and its president, Manabu Yamamoto, are committed to contributing to the sound development of society while sincerely tackling the challenges that society is now confronting.

[For Inquiries about This Press Release from Media]

Corporate Communications Dept. Tel : +81-3-5290-5511

[For Inquiries from Medical Personnel]

Life Innovation Dept. Vaccines and Diagnostics Business Headquarters Dept. Tel : +81-3-6214-3235